glucose, (beta-d)-isomer has been researched along with Glucose Intolerance in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 11 (91.67) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
Authors | Studies |
---|---|
Badakhshi, Y; Brubaker, PL; Jin, T; Ling, W; Ning, H; Shao, W; Song, Z; Tian, L; Yang, BB | 1 |
Bona, NP; Carvalho, FB; Chaves, VC; Gutierres, JM; Lencina, CL; Mendonça, LT; Oliveira, PS; Reginatto, FH; Soares, MSP; Spanevello, RM; Stefanello, FM; Vasconcellos, FA; Vieira, A; Vizzotto, M | 1 |
Atsumi, T; Cho, KY; Hatanaka, KC; Kameda, H; Kitao, N; Miyoshi, H; Nakamura, A; Nomoto, H; Omori, K; Takagi, R; Takahashi, K; Terauchi, Y | 1 |
Pinto Pereira, L; Rambaran, K; Teelucksingh, S | 1 |
Hayashizaki, Y; Imamura, M; Kihara, R; Kobayashi, Y; Kurosaki, E; Li, Q; Noda, A; Sasamata, M; Shibasaki, M; Tahara, A; Takasu, T; Tomiyama, H; Yamajuku, D; Yokono, M | 1 |
Alameddine, A; Ayer, A; Bourreau, J; Custaud, MA; Derbre, S; Fajloun, Z; Gauguier, D; Gauquelin-Koch, G; Navasiolava, N; Yuan, M | 1 |
Astiarraga, B; Baldi, S; Bizzotto, R; Ferrannini, E; Frascerra, S; Heise, T; Mari, A; Muscelli, E; Pieber, TR | 1 |
Hemmingsen, B; Krogh, J; Metzendorf, MI; Richter, B | 1 |
Amini, S; Eriksson, JW; Johnsson, E; Lundkvist, P; Pereira, MJ; Sjöström, CD | 1 |
Abdul-Ghani, M; Adams, J; Al Jobori, H; Cersosimo, E; Daniele, G; DeFronzo, RA; Triplitt, C | 1 |
Andrikopoulos, S; Joannides, CN; Lamont, BJ; Mangiafico, SP; Waters, MF | 1 |
Fukazawa, M; Fukuzawa, T; Hagita, H; Honda, K; Ikeda, S; Kawabe, Y; Kawai, M; Kawai, T; Kobayashi, T; Ozawa, K; Sato, T; Suzuki, M; Takeda, M; Yata, T | 1 |
1 review(s) available for glucose, (beta-d)-isomer and Glucose Intolerance
Article | Year |
---|---|
Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fasting; Glucose Intolerance; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
3 trial(s) available for glucose, (beta-d)-isomer and Glucose Intolerance
Article | Year |
---|---|
Sodium-glucose cotransporter 2 inhibition as a potential treatment for idiopathic oedema.
Topics: Anxiety; Autonomic Nervous System; Benzhydryl Compounds; Blood Pressure; Cross-Over Studies; Edema; Electrolytes; Female; Glucose Intolerance; Glucosides; Hemodynamics; Humans; Models, Theoretical; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2019 |
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Energy Metabolism; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Lipolysis; Membrane Transport Modulators; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2016 |
Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
Topics: Adipose Tissue; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Double-Blind Method; Drug Therapy, Combination; Exenatide; Female; Glucose Intolerance; Glucosides; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Magnetic Resonance Imaging; Male; Middle Aged; Nausea; Obesity; Peptides; Prediabetic State; Treatment Outcome; Venoms; Weight Loss | 2017 |
8 other study(ies) available for glucose, (beta-d)-isomer and Glucose Intolerance
Article | Year |
---|---|
Dietary Cyanidin-3-Glucoside Attenuates High-Fat-Diet-Induced Body-Weight Gain and Impairment of Glucose Tolerance in Mice via Effects on the Hepatic Hormone FGF21.
Topics: Animals; Anthocyanins; Diet, High-Fat; Dietary Fats; Fibroblast Growth Factors; Gene Expression Regulation; Glucagon-Like Peptide 1; Glucose Intolerance; Glucosides; Incretins; Leptin; Liver; Male; Mice; Random Allocation; Weight Gain; Weight Loss | 2020 |
Southern Brazilian native fruit shows neurochemical, metabolic and behavioral benefits in an animal model of metabolic syndrome.
Topics: Animals; Anthocyanins; Antidepressive Agents; Antioxidants; Behavior, Animal; Brazil; Catalase; Corpus Striatum; Diet, Carbohydrate Loading; Disease Models, Animal; Glucose Intolerance; Glucosides; Hippocampus; Hypoglycemic Agents; Hypolipidemic Agents; Metabolic Syndrome; Neuroprotective Agents; Oxidative Stress; Plant Extracts; Psidium; Rats; Rats, Wistar; Tandem Mass Spectrometry; Weight Gain | 2018 |
Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice.
Topics: Animals; Benzhydryl Compounds; Fatty Acids; Gene Expression; Glucose Intolerance; Glucosides; Hypoglycemic Agents; Insulin Glargine; Insulin-Secreting Cells; Lipid Metabolism; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2019 |
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
Topics: Albuminuria; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Fatty Liver; Glomerular Filtration Rate; Glucose Intolerance; Glucosides; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Inflammation; Kidney; Liver; Male; Oxidative Stress; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Thiophenes | 2014 |
The cardiovascular effects of salidroside in the Goto-Kakizaki diabetic rat model.
Topics: Animals; Aorta; Blood Pressure; Cardiotonic Agents; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Endothelium, Vascular; Glucose Intolerance; Glucosides; Guanylate Cyclase; Heart Rate; Hyperglycemia; Hypertension; Male; Myocytes, Smooth Muscle; Nitric Oxide Synthase Type III; Phenols; Rats; Rats, Inbred WKY; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Vasodilation | 2015 |
Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Ketones; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity.
Topics: Adipose Tissue, White; Adiposity; Animals; Benzhydryl Compounds; Cell Size; Gene Expression Regulation; Glucose Clamp Technique; Glucose Intolerance; Glucose Transporter Type 4; Glucosides; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Male; Membrane Transport Modulators; Muscle, Skeletal; Phosphoenolpyruvate Carboxykinase (GTP); Rats, Transgenic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Gain | 2017 |
Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucose Intolerance; Glucose Tolerance Test; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Kidney; Male; Mice; Mice, Inbred Strains; Rats; Rats, Sprague-Dawley; Rats, Zucker; Sodium-Glucose Transporter 2 Inhibitors | 2012 |